ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17 Septiembre 2024 - 3:00AM
- Existing investors and new investor Double Point
Ventures join forces to support ImmunOs Therapeutics
- Investment secures funding of ongoing promising
clinical trial of IOS-1002 in solid cancers
September 17, 2024 – ImmunOs Therapeutics AG, a
biopharmaceutical company leveraging its unique immune system
modulating HLA-based technology platform to develop first-in-class
therapeutics for the treatment of cancer and autoimmune diseases,
today announced the closing of a Series C financing round of $11
million. The round was led by existing investors Gimv, Pfizer
Ventures, Mission BioCapital, BioMed Partners and supported by new
investor Double Point Ventures as well as other existing investors.
In conjunction with the round, Steve Tregay, PhD, Managing General
Partner of Mission BioCapital, has joined the Company’s Board of
Directors.
Proceeds from the Series C will be used to
further fund the ongoing clinical trial of ImmunOs’ lead program
IOS-1002 to completion of the Phase Ia dose escalation clinical
trial as a monotherapy and in combination with MSD’s (Merck &
Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA®
(pembrolizumab). IOS-1002 is a novel, multifunctional immunotherapy
agent for the treatment of advanced solid tumors that
simultaneously targets several immune checkpoints. It is based on a
naturally occurring human leukocyte antigen (HLA) targeting LILRB1
(ILT2), LILRB2 (ILT4), and KIR3DL1 and designed to activate both
innate and adaptive immune cells to modulate the tumor
microenvironment, potentially also enhancing the effectiveness of
existing IO treatments such as KEYTRUDA.
"We are delighted to close this important
financing round with existing and new investors," said Reinhard
Ambros, Executive Chairman of the Board of ImmunOs Therapeutics.
"The raise underlines the high interest in this space and
potentially highly relevant therapeutic option of our
well-differentiated lead program. The funding allows us to proceed
with our lead program IOS-1002 as monotherapy and in combination
with KEYTRUDA. IOS-1002 is the most advanced HLA-based program
worldwide addressing these relevant targets and offering such a
novel, multifunctional immunotherapy approach.”
“We are excited to invest in ImmunOs
Therapeutics with its large potential as a first-in-class
immunotherapy approach for the treatment of both solid and liquid
tumors,” Campbell Murray, Advisor at Double Point Ventures said.
“We look forward to supporting ImmunOs’ success.”
“We believe that ImmunOs Therapeutics’ unique
platform is well-positioned to deliver potential innovative
approaches in inflammatory diseases and immuno-oncology,” Michael
Baran, Partner at Pfizer Ventures added. “We look forward to the
opportunity to review clinical data potentially in 2025.”
“The Company is well differentiated to exploit
its potentially first-in-class immunotherapy for the benefit of
patients with limited therapeutic options. ImmunOs’ approach of
identifying HLA molecules with naturally tailored affinity and
specificity profiles is not just elegant but also truly
differentiated,” stated Andreas Jurgeit, PhD, Partner at Gimv. “We
are extremely excited by the progress being made at ImmunOs and
proud to support the team further towards clinical validation for
the benefit of patients.”
“ImmunOs Therapeutics has a very innovative
approach to target myeloid checkpoints which are potentially the
next major breakthrough in immuno-oncology,” said Steve Tregay,
Managing General Partner at Mission BioCapital. “We look forward to
enable more exciting data from the clinical trials of
IOS-1002.”
ImmunOs Therapeutics is committed to advancing
the clinical development of IOS-1002 and exploring its potential to
improve the lives of cancer patients.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
###
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG leverages its unique
immune system modulating HLA-based technology platform to develop
first-in-class therapeutics for the treatment of cancer and
autoimmune diseases. ImmunOs’ lead program is a multi-functional
HLA-fusion protein that binds specific LILRB (leukocyte
immunoglobulin-like) and KIR (killer cell immunoglobulin-like)
receptors and can stimulate both the innate and the adaptive immune
systems of cancer patients to eliminate tumor cells. ImmunOs is
also developing different modalities to agonize receptors for the
modulation of the immune system in autoimmune diseases.
The Company is supported by leading
international investors and is located in Schlieren,
Switzerland. For more information, please visit
www.immunostherapeutics.com.
Company ContactImmunOs Therapeutics AG
Wagistrasse 188952 Schlieren (Zurich Area),
Switzerlandinfo@immunostherapeutics.com
Media InquiriesakampionDr. Ludger Wess /
Ines-Regina Buth Managing Partnersinfo@akampion.comTel. +49 40 88
16 59 64 /Tel. +49 30 23 63 27 68